Abstract
Alopecia areata (AA) is a common autoimmune skin disease that results in the loss of hair on the scalp and elsewhere on the body and affects over 146 million people worldwide at some point in their lives. Founded in 1981, the National Alopecia Areata Foundation is a nonprofit organization that supports research to find a cure or acceptable treatment for AA, supports those with the disease, and educates the public about AA. The National Alopecia Areata Foundation conducts research summits every 2 years to review progress and create new directions in its funded and promoted research. The Foundation brings together scientists from all disciplines to get a broad and varied perspective. These AA research summits are part of the Foundation's main strategic initiative, the AA Treatment Development Program, to enhance the understanding of AA and accelerate progress toward a viable treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | S3-S8 |
| Journal | Journal of Investigative Dermatology Symposium Proceedings |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2018 |
Bibliographical note
Funding Information:Funding for the Summit and the publication of this supplement was provided by the National Alopecia Areata Foundation and was made possible (in part) by a grant (1 R13AR071266) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and sponsorship support by Pfizer, BiologicsMD, Gilead, LEO Pharma, Aclaris, Concert, Galderma, Incyte, and RXi. NAM has served on an advisory board for BiologicsMD. MKH has received grant support from Incyte and NAAF and has served as a consultant for BiologicsMD and Concert Pharmaceuticals. AMC has served as a consultant for Aclaris Therapeutics and has received grant support from National Institutes of Health, Pfizer, and NYSTEM. The other authors state no conflict of interest.
Funding Information:
Funding for the Summit and the publication of this article was provided by the National Alopecia Areata Foundation. Funding for this Summit was also made possible (in part) by a grant (1 R13AR071266) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Publisher Copyright:
© 2017 The Authors